initi outperform pt
would honor would join us o/p
path normal profit growth aid strong capit alloc
decidedli neg rx suppli chain much
one stock prefer given histor
capit alloc prowess chang valu unlock although
provid accept return road travel
much challeng volatil origin perceiv share
ralli nearli sinc oct although would foolish
call bottom industri econom contend number
key pressur hit profit past certainli
start abat thu view begin see
normal core profit growth lsd rang coupl
capit deploy see ep growth return near
coupl attract financi arbitrag relat chang
transact see appeal risk reward nt
particularli found floor rel valuat furthermor
see nois around amzn entri channel misplac
given effici wholesal fact drug buy
alreadi massiv consolid without threat extern disrupt
see period resum margin stabil ahead upward
movement overal rate like tie mix acquisit vs core
expans all-in make current yield appear real
grow allow particip valu mean revers
one main tenant hous macro equiti call given
dynam see risk reward favor thu initi share
o/p rate
thing watch gmx trajectori tone gener drug price
time chang ipo
debat recent pharma headwind abat
much valu arbitrag exist chang right
long term growth rate
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk potenti resumpt independ
price war result materi margin degrad signific profit
pressur reimburs pressur uk continent europ
harm celesio growth question intern expans
polit threat chang rx price methodolog gross net
intens scrutini opioid curtail na distribut profit increment
price pressur share loss medic distribut busi
on-line competit name signific downtick sell-sid
gener deflat without similar movement buy side margin result
overal compress inabl transit specialti contract
long term new econom allow fair payment differenti
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
would honor would join us o/p
last page report import disclosur regard stock report
tabl content
debat recent pharma headwind abat
debat much valu arbitrag exist chang
debat right long term growth rate
financi model renorm headwind
point differenti vs st
iv valuat risk price disrupt vs histori
 conclus initi outperform less bad thesi
materi de-rat estim led collaps share
enter european distribut retail via
major acquisit celesio
creativ structur w/ mt
thesi na rx market headwind abat chang
valu unlock build momentum recent
action allow growth reacceler
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk notabl chang gross net price outlook
coupl degrad independ pharmaci
revenu bias na despit increas intenational push
hammer regard amongst best class within hc
presid ceo sinc chairman sinc
previous pre suppli manag
evp pharma medical-surg
previous cfo us pharma specialti health
although recent turnov
departur jame beer paul julian mark walchirk
deep manag bench execut
debat recent pharma headwind abat
independ price war impact complet
gener deflat steadi hsd ldd
independ market rel fluid independ shop
best price within complianc rang disti
provid financi incent gpo gain share
fall recent round independ re-pric
start like unintend size
real share shift match
distributor forc lower guidanc
earn call note
fulli lap impact sell-sid price
environ continu remain competit less
number hyperinfl buy side
number hyperinfl sell side
bring nt relief uk headwind
roll start ep
part uk govern auster measur
nation health servic nh ask cut bn
pharmaci
lost reimburs estim
per pharmaci april march
consequ announc closur
lloydspharmaci charg home deliveri
philip hammond recent releas autumn budget
restor fund nh though impact
given mck fiscal year compani larg
cut addl cut current slate
potenti addit ep risk move remaind distribut contract
away
recent headwind lessen increasingli manag head
debat much valu arbitrag exist chang
ipo valu unlock multipl arb like
format new creat one
current trade ebitda
largest hit compani us
contribut solut connect
analyt imag workflow
solut busi retain relayhealth
result organ attract
asset offer end-to-end payment
solut target provid payer consum
compani process trillion transact per
year servic top plan
ebitda transact announc
given potenti ipo ebitda rang
issuanc primari share chang could pay
mm bn debt
would result addit valu per
share central scenario rang
tax advantag structur provid bn proce sharehold medium term
blackston hold compani ipo creat public price
spin stake sharehold tax effici manner
proce bn blackston complet exit
receiv bn
mm
expect
reflect financi provid chang healthcar file per manag commentari
debat right lt growth rate
grandpa us pharma busi anymor
reduc pharma ad intenational specialti
spent much past five year total
transform busi away tradit focu
us pharma mani headwind face
uniprix etc europ celesio udg asset
sold ei plan ipo/spin chang
healthcar acquisit covermym
almost acquisit higher margin/growth vs base
headwind growth return lsd msd
see normal lt oi growth rang w/ increment upsid
model summari point differenti vs street
swing factor state gener deflat pace take-out broadli cadenc capit alloc
point
momentum
balanc
in-lin moder
discount market vs
histor average
million except per share data fy end march organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate vs prior reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris carri valu total valu valu per perpetu growth valu enterpris enterpris valu reflect book valu ownership discount back pv cash proce close januari
valuat collaps trough level recent
period multipl compress given heighten uncertainti ep de-rat rel valuat set improv
risk point favor risk reward profil threat price om compress fresh investor mind
potenti resumpt independ price war result materi margin degrad signific profit pressur
reimburs pressur uk continent europ harm celesio growth question intern expans
polit threat chang rx price methodolog gross net intens scrutini opioid curtail na distribut profit
increment price pressur share loss medic distribut busi on-line competit name
signific downtick sell-sid gener deflat without similar movement buy side margin result overal compress
inabl transit specialti contract long term new econom allow fair payment differenti servic
conclus initi outperform pt upsid
favor share less bad thesi w/ growth like acceler arbitrag
decidedli neg rx suppli chain much one
stock prefer given histor capit alloc prowess chang valu unlock
although provid accept return road travel much
challeng volatil origin perceiv share ralli nearli sinc oct
although would foolish call bottom industri econom contend
number key pressur hit profit past certainli start abat
thu view begin see normal core profit growth
lsd rang coupl capit deploy see ep growth return near
coupl attract financi arbitrag relat transact
see appeal risk reward nt particularli found floor rel valuat
furthermor see nois around amzn entri channel misplac given
effici wholesal fact drug buy alreadi massiv consolid
without threat extern disrupt see period resum margin stabil ahead
upward movement overal rate like tie mix acquisit vs core expans
all-in make current yield appear real grow allow
particip valu mean revers one main tenant hous macro equiti call
given dynam see risk reward favor thu initi share o/p rate
thing watch gmx trajectori tone gener drug price time chang ipo
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
